<?xml version="1.0" encoding="UTF-8"?>
<p>Tocilizumab, a humanized monoclonal antibody against interleukin-6, is an immunosuppressive drug intended primarily for the treatment of rheumatoid arthritis [
 <xref rid="B113-jcm-09-01917" ref-type="bibr">113</xref>]. In China, it was expected to have a beneficial effect on coronavirus patients with severe lung damage and elevated interleukin six levels [
 <xref rid="B113-jcm-09-01917" ref-type="bibr">113</xref>,
 <xref rid="B114-jcm-09-01917" ref-type="bibr">114</xref>]. In one of nonrandomized, open-label clinical studies involving 21 patients with severe or critical COVID-19 treated intravenously with tocilizumab it has been shown that in 15 out of 20 patients (75%), there was a statistically significant decrease in oxygen demand from the fifth day after receiving tocilizumab. Additionally, in 19 patients (90.5%), CT scan showed resolution of radiological abnormalities [
 <xref rid="B115-jcm-09-01917" ref-type="bibr">115</xref>].
</p>
